GlassScriptPhysician profile
Mary J Baxter
NPI 1154416444
$2,525.02
in general payments reported to CMS, 2019-2025
25 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $419 · 2023: $225 · 2024: $309 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037 · Travel and Lodging: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.37 |
| Travel and Lodging | $753.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $1,018.13 | 2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $240.86 | 2021-2024 | |
| Boston Scientific Corporation | $138.48 | 2021-2025 | Watchman Access System, Energen Icd, Bodyguardian |
| Amgen INC. | $134.38 | 2021-2022 | |
| Edwards Lifesciences Corporation | $118.58 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Medtronic, INC. | $113.15 | 2021-2025 | Azure Xt Dr Mri Surescan, Micra |
| Actelion Pharmaceuticals US, INC. | $98.77 | 2021-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $82.39 | 2021-2024 | Xarelto |
| Scpharmaceuticals INC. | $72.80 | 2024-2025 | |
| Pfizer INC. | $61.72 | 2021-2025 | |
| Amarin Pharma, INC. | $53.81 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $47.49 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $47.01 | 2022-2025 | Verquvo, Bridion |
| E.R. Squibb & Sons, L.L.C. | $44.53 | 2021-2025 | Camzyos |
| Chiesi USA, INC. | $43.20 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.48 | 2021-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $31.82 | 2021 | |
| Cvrx, INC. | $27.92 | 2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $23.11 | 2025 | Attruby |
| Abiomed | $21.17 | 2024 | Impella |
| Alexion Pharmaceuticals, INC. | $19.05 | 2021 | |
| Philips North America LLC | $15.74 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.